InsiderTrades

Form 4 for RGNX REGENXBIO Inc.

Accepted 2022-01-04 00:00:00 ET · period of report 2022-01-01 · accession 0001562180-22-000168 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-01-04 2022-01-01 RGNX Simpson Curran Chief Oper, Tech. Off F - Tax $32.70 -1,332 16.4K -8% -$43.6K
D 2022-01-04 2022-01-03 RGNX Simpson Curran Chief Oper, Tech. Off A - Grant $0.00 +10.7K 27.1K +65% $0
D 2022-01-04 2022-01-03 RGNX Simpson Curran Chief Oper, Tech. Off A - Grant $0.00 +51.1K 51.1K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-01-01 F D 1,332 $32.70 16,416 D — —
2 Common Common Stock 2022-01-03 A A 10,700 $0.00 27,116 D — — (F1) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer.
3 Derivative Stock Option (Right to Buy) 2022-01-03 A A 51,100 $0.00 51,100 D $34.31 · — to 2032-01-03 51,100 Common Stock (F2) 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.